Erlotinib has an acceptable toxicity profile in patients with myelodysplastic syndrome (MDS) and anti-leukemic activity in higher-risk MDS patients after failure of hypomethylating agents, results of an interim analysis of a phase 2 trial have found. The study was presented at the 52nd American Society of Hematology Meeting and Exposition.
All articles by Traci Dantoni
Patients with previously treated chronic lymphocytic leukemia (CLL) who subsequently received oral forodesine, a purine nucleoside phosphorylase (PNP) inhibitor, had a response rate of 26%, an analysis of an open-label, multicenter, phase 2 study has found. The study as presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.